X

Granules India Ltd Q2FY24; 30% fall in Profits

Granules India Ltd and its subsidiaries are primarily involved in the manufacturing and selling of Active Pharma Ingredients (APIs), Pharmaceutical Formulation Intermediates (PFIs) and Finished Dosages.

Financial Results:

Granules India Ltd reported Revenues for Q2FY24 of ₹1,189.00 Crores up from ₹1,151.00 Crore year on year, a rise of 3.3%.

Total Expenses for Q2FY24 of ₹1,056.00 Crores up from ₹965.00 Crores year on year, a rise of 9.43%.

Consolidated Net Profit of ₹102.00 Crores down 29.66% from ₹145.00 Crores in the same quarter of the previous year.

The Earnings per Share is ₹4.21, down 27.91% from ₹5.84 in the same quarter of the previous year.

*It is important to note that the way the results have been accounted for are slightly different than the ones the companies may choose to publish.

*The presented data is automatically generated. It may occasionally generate incorrect information.

Related Post